TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01381016

Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol
Description: Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.

Intervention type: DRUG
Group type: OTHER
Intervention: Gonadotropin-releasing hormone (GnRH)
Description: Pituitary response was assessed to determine how estradiol administration alters pituitary sensitivity to GnRH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH)
Description: Pituitary response was assessed to determine how estradiol administration alters pituitary sensitivity to GnRH.

Intervention type: DRUG
Group type: OTHER
Intervention: Progesterone
Description: Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.
Study: NCT01923506

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02373943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: β-carotene supplemented maize
Description: Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene supplemented maize
Study: NCT00851357

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nicotine patch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Materials
Description: Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Materials
Description: Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Materials
Description: Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day.
Study: NCT02373943

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal (non biofortified) maize without added β-carotene
Description: Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of normal maize
Study: NCT01805401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Anode placed over the OFC or the DLPFC and cathode placed over the occipital region

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Anode placed over the OFC or the DLPFC and cathode placed over the occipital region

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Anode placed over the OFC or the DLPFC and cathode placed over the occipital region
Study: NCT02585232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling (C)
Description: The counseling component incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework. Counseling sessions will be completed for 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Consultation (CC)
Description: Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment, which then immediately shapes development of concrete action plans.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Consultation (CC)
Description: Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment, which then immediately shapes development of concrete action plans.
Study: NCT03912246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological samples
Description: collection of blood, urine, saliva, stool, skin and mouth swabs, tears

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological samples
Description: collection of blood, urine, saliva, stool, skin and mouth swabs, tears

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar puncture
Description: collection of cerebrospinal fluid
Study: NCT02443974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brace (Fisiotensor®)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleeve (Fisiotensor®)
Study: NCT00942565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol/acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Study: NCT02472860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Cognitive Training (TCT)
Description: The investigators have selected a set of computer exercises designed to specifically target aspects of cognition relevant to autism spectrum disorder (including attention and executive functions). The tasks were designed to benefit subjects through principles of learning dependent plasticity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Youth Appropriate Online Games
Description: Engaging games not designed to improve cognition
Study: NCT04803266

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal mammary node irradiation
Description: Regional nodal irradiation including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: No internal mammary node irradiation
Description: Regional nodal irradiation not including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
Study: NCT03038321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofenacin
Description: solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tavanic
Description: levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xefo
Description: lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
Study: NCT00637065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: Bosentan tablets - 62.5mg bd for first 4 weeks, then 125mg bd if tolerated until trial completion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tables - identical to active drug but without the active ingredient -
Study: NCT06514872

Intervention type: OTHER
Intervention: prevalance and determinants of home accidents
Description: home accidents among Turkish older
Study: NCT01239069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-110 ophthalmic suspension high dose
Description: ophthalmic suspension; high dose; QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-110 ophthalmic suspension low dose
Description: ophthalmic suspension; low dose; QID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DE-110 ophthalmic suspension vehicle;QID
Study: NCT02329470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Withdrawal of continuous positive airway pressure treatment
Description: Withdrawal of continuous positive airway pressure treatment
Study: NCT00472225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab Induction: Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks~Rituximab Maintenance: Rituximab 375 mg/m2 monthly IV for 4 consecutive months
Study: NCT03976765

Intervention type: OTHER
Intervention: Rehabilitation program
Description: The patients follow different rehabilitation programs (surgery, anesthetic, post-operative). Hospital discharge is authorized only after validation of objective, clinical and para clinic criteria
Study: NCT01178463

Intervention type: OTHER
Intervention: Biospecimen staining
Description: The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.

Intervention type: OTHER
Intervention: Biospecimen staining
Description: The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
Study: NCT00670215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin single dose
Description: Patients randomized to this regimen will receive a single-dose of ciprofloxacin MR 1000 mg PO approximately 2 to 3 hours prior to the TRNBP. Patients will also receive two doses of matching placebo approximately 24 hours prior to and approximately 24 hours after the TRNBP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin triple dose
Description: Patients randomized to this regimen will receive three doses of ciprofloxacin MR 1000 mg PO. The doses will be approximately 24 hours prior to the TRNBP, approximately 2 to 3 hours prior to the TRNBP, and approximately 24 hours after the TRNBP.
Study: NCT00866463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Single Dose of 50 mg Sildenafil Oral Tablet With Water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Single Dose of 50 mg Sildenafil Experimental Tablet With Water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
Study: NCT04623788

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI with contrast

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI with contrast

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI with contrast

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI with contrast
Study: NCT01292941

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent catheterisation
Description: Speedicath, Intermittent catheterisation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NonCE marked intermittent catheter/red
Description: Paris, Intermittent catheterisation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NonCE marked intermittent catheter/green
Description: Paris, Intermittent catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NonCE marked intermittent catheter/blue
Description: Paris, Intermittent catheter
Study: NCT00404651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T vaccine
Description: 0.5 mL, intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T vaccine
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T vaccine
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-HBV-IPV vaccine
Description: 0.5 mL, IM
Study: NCT04052490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abutment with flat occlusal reduction with feather edge finish
Description: Non vital teeth require a full coverage restoration to withstand the functional stresses and prevent any further destruction of tooth/crown complex. The zirconia all-ceramic crowns yield a high flexure strength and are used as an esthetic alternative to ceramo-metallic crowns. Several studies linked the effect of preparation designs to the survival of the restoration. Others, studied the effect of the finish line geometries as deep chamfer and shoulder on the marginal integrity of restorations. The feather edge finish line is used with zirconia crowns with limited data regarding its success. However, there is no presented research dealing with the effect of finishing line designs in combination with different occlusal reduction schemes on the marginal fit of full contour zirconia crowns.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abutment with flat occlusal reduction with feather edge finish
Description: Non vital teeth require a full coverage restoration to withstand the functional stresses and prevent any further destruction of tooth/crown complex. The zirconia all-ceramic crowns yield a high flexure strength and are used as an esthetic alternative to ceramo-metallic crowns. Several studies linked the effect of preparation designs to the survival of the restoration. Others, studied the effect of the finish line geometries as deep chamfer and shoulder on the marginal integrity of restorations. The feather edge finish line is used with zirconia crowns with limited data regarding its success. However, there is no presented research dealing with the effect of finishing line designs in combination with different occlusal reduction schemes on the marginal fit of full contour zirconia crowns.
Study: NCT02028377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: PET/MRI
Study: NCT00367328

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1320nm Nd: YAG nonablative laser
Description: a 4 mm piece of skin tissue (about the size of a pencil-head eraser) from the affected area. This procedure is called a punch biopsy and will be done to confirm your diagnosis. A culture swab similar to a Q-Tip will be used to wipe the affected areas during the first visit to determine any bacteria that may be present. A survey with questions will be given at the first visit, again after 3 months and at the last visit to measure the success of the treatment. Photographs will be taken prior to each treatment and one month following your last treatment. A laser, which is a very powerful light, will be used to treat half of the skin that is affected by your condition.
Study: NCT02539771

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography and blood sample
Description: Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography and blood sample
Description: Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography and blood sample
Description: Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic
Study: NCT01383746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yttrium microsphere injection
Description: Radiation therapy
Study: NCT04356495

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Vitamins
Description: 2 tablets daily from the first day (day 0) to day 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: 1 tablet daily from the first day (day 0) to day 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Description: 2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon β-1b
Description: A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water
Study: NCT01755364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-V
Study: NCT00350025

Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: Cetuximab 250mg/m2 IV weekly for each 28 day cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: Cetuximab 250mg/m2 IV weekly for each 28 day cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.
Study: NCT03707795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
Description: Participants will be given four IM injections throughout the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
Description: Participants will be given four IM injections throughout the study
Study: NCT04291612

Intervention type: OTHER
Intervention: Physical exam
Description: Part 2 participants will be prospectively followed clinically for relapse for 30 months from the date of surgery for physical examination at post-ops visits.
Study: NCT04243694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Participants of the intervention group will receive 6-weeks of mindfulness training.
Study: NCT01972581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reaction Time Training
Study: NCT03689023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A controlled multimodal intervention
Description: The intervention is interdisciplinary, multimodal and patient activating and uses the existing setting and work flows at the Clinic as well as new interventions, ensuring that the patients receive education about cardiovascular risk factors, physical activity and healthy diet through a systematic approach including targeted patient education
Study: NCT02063204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: selumetinib 50 mg (2x25mg) administered by mouth as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: selumetinib 50 mg (2x25mg) administered by mouth as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: selumetinib 50 mg (2x25mg) administered by mouth as capsules
Study: NCT02211053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: 20 mg IV bolus + 10 mg/h infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04126694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT with smartphone application SenseSupport
Description: SenseSupport intervention system used as an augment to a 12 week in-person CBT treatment for transdiagnostic binge eating pathology
Study: NCT03263546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT)
Description: Participants will receive internet-delivered CBT with therapist support for 16 weeks. The treatment consists of 14 online chapters with interactive features as videos and illustrations. The treatment has the main focus on exposure with ritual prevention. The children and parents have regular contact with a personal assigned therapist via written text messages in the platform.~Participants that are classified as non-responders at 3 months follow-up will receive face-to-face CBT of up to 12 sessions over 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants in the gold standard group will receive 14 individual face-to-face CBT sessions over 16 weeks. The treatment is based on current evidence based recommendations for OCD, and focuses on exposure with ritual prevention.~Participants that are classified as non-responders at 3 months follow-up will receive additional face-to-face CBT of up to 12 sessions over 12 weeks.
Study: NCT05487521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and or prednisolone
Description: we gave methylprednisolone and or prednisolone to patients with EEG activity and follow up the effect of the drug on language
Study: NCT01149317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Weekly acupuncture treatment for up to 14 weeks to augment usual care
Study: NCT03253042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WBV exercise program
Description: The intervention will consist of a 8-week whole-body vibration exercise program with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham WBV exercise program
Description: The intervention will consist of a 8-week exercise program, but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.